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ABSTRACT

TIED TOGETHER: A MOLECULAR ROLE FOR TIE1 IN ANGIOPOIETIN TIE2
SIGNALING
By Tom Conrad Maugans Seegar
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Director: Dr William A. Barton
Assistant Professor, Department of Biochemistry and Molecular Biology

The primary function of the vascular system is the maintenance of oxygen
homeostasis for all metazoan tissue. Angiogenesis, the remodeling and maintenance of
new blood vessels from an existing vessel, is primarily controlled through the endothelial
specific receptor tyrosine kinase Tie2, and the orphan receptor tyrosine kinase, Tie1.
Although these receptors share highly conserved, genetic and biochemical analysis has
shown these receptors have distinct and essential roles in angiogenesis. Tie2 activation
typically results in vessel stability and quiescences and has further been shown to interact
with all four sub-types of the angiopoietin signaling factors, Ang1-4. Conversely, Tie1 is
involved in vascular remodeling and has no known ligands. The aim of this study is to
resolve the molecular mechanism in which Tie1 modulates Angiopoietin-induced Tie2
signaling. Using biophysical, structural, and biochemical assays we show Tie1 directly

interacts with Tie2 via electrostatic interactions housed within the extracellular domains.
The binding of Tie1 to Tie2 attenuates Tie2 phosphorylation. We further show the
constitutive agonist of Tie2, Ang-1, is capable of excluding Tie1 initiating Tie2
activation. Whereas the antagonist, Ang-2, is in incapable of excluding Tie1. Finally, we
identify a region within the angiopoietin receptor-binding domain that is capable of
including or excluding Tie1 from Tie2. Based upon the available data, we provide a
model for Angiopoietin-induced Tie2 signaling.
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Chapter 1
Introduction

1.1.1 Vasculogenesis and Angiogenesis
All metazoan species have developed a means in which oxygen homeostasis can
be maintained. Simple metazoans consisting of a few thousand cells rely on simple
oxygen diffusion where more complex organisms such as Drosophila melanogaster, in
which diffusion is not possible, have developed a specialized tracheal tube network to
maintain oxygen homeostasis (Gorr et al., 2006).

In larger bodied vertebrates, a

significantly more complex closed vascular system has developed to maintain oxygen
homeostasis while simultaneously serving as a means to traffic nutrients and metabolic
waste. Proper development and maintenance of the vascular system is essential to the
organisms’ health.
Development of the cardiovascular system during embryogenesis is divided into
two sequential processes: vasculogenesis and angiogenesis (Figure 1.1). Vasculogenesis
occurs first with its onset centered on embryonic day 3 in mice. Initially, endothelial
progenitor cells, angioblasts, differentiate from embryonic stem cells.

Angioblasts

sequentially migrate to sites of vascularization, where they continue their differention to
form the primordial heart and the primary plexus. The vascular endothelial growth factor
receptor (VEGFR) and its cognitive ligand, VEGF, are essential for this process. Mouse
knockout studies of the VEGFR2 tyrosine kinase are embryonic lethal as a result of
improper angioblast migration to sites of noevascularization (Shalaby et al., 1997). This
process is essential for formation of the primary plexus, a honeycomb like network of
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Figure 1.1: Vascular Development. (A.) The vascular development proceeds through
vasculogenesis with the formation of the primary plexus. (B.) Secondly, angiogenesis
occurs with the remodeling of the primary plexus into a mature vascular system. (C.)
Vascular sprouting requires cooperation between both Tie and VEGF family receptors,
whereas regression only utilizes Tie family signaling.

3

A.

B.
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differentiated cells that express the endothelial specific markers: vascular endothelium
growth factor receptor (VEGFR2), Tie1, Tie2, and vascular endothelium (VE)-cadherin
(Li et al, 2009).
The onset angiogenesis begins at approximately embryonic day 10 in mice.
During this stage remodeling of the primary plexus begins, forming a mature vascular
bed into vessels. The vessels are lined by a layer of connective endothelial cells that are
surrounded by a supportive cellular coating, consisting of smooth muscles cells and
pericytes. Angiogenesis is continual throughout development and persists in adulthood.
Vascular sprouting and regression require proper coordination of multiple cellular
signals, most notably through the endothelial specific VEGF and Tie family receptor
tyrosine kinases (RTK). Vascular homeostasis, sprouting, and regression all require
changes in Tie signaling whereas the VEGF signaling only appears to be involved in
vessel sprouting (Figure 1.1). While there is a wealth of information on the molecular
mechanisms of VEGFR family, the mechanistic roles of Tie family receptors and the
cognitive angiopoietin ligands remain controversial and poorly understood (Augustin et
al., 2009). Therefore, mechanisms affecting angiopoietin induced Tie family receptor
signaling remains the focus of the following study.

1.2.1 Pathological Angiogenesis
The influential studies of Judah Folkman, were the first to describe the necessity
of the vascular system in tumor growth and metastasis (Folkman, 1971). As such, he
hypothesized an avascular tumor growing devoid of vascular support would not exceed 12mm in size, limited by the diffusion rate of nutrients and waste across the spherical
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mass. This proposed limit results from equivalent rates of cellular proliferation and death
to be come equal resulting in no net change in tumor size. Therefore, blood vessel
recruitment could potentially increase tumor volume via efficient removal of cellular
waste and nutrient replenishment.

These observations further suggest that anti-

angiogenic compounds could have considerable therapeutic potential by limiting
tumorigenesis.
In contrast to developmental angiogenesis, pathological angiogenesis, as depicted
in Figure 1.2, typically begins with the formation of an avascular tumor growing in the
subcutaneous space detached from the vasculature. Over expression of VEGF and other
angiogenic factors promote tumor growth and development. Rapid cellular growth of the
tumor results in hypoxia, causing the release of pro-angiogenic factors, such as VEGF
and Ang-2, which diffuse to the vascular endothelium. Initial affects of these growth
factors include the disintegration of the vascular basement membrane by matrix
metalloproteinase’s.

Commonly, these pro-angiogenic factors consist of VEGF-A

binding to its endothelial cell receptor VEGFR2 and Ang-2 binding to its receptor Tie2
(Shibuya, 2008; Gale et al., 1999). Deactivation of Tie2 by Ang2 leads to induction of
additional chemoattractants that promote endothelial cell migration and mitogenesis
(Holash et al., 1999).

Interestingly, in the absence of VEGF stimulation through

VEGFR2, newly forming vessels retract, when endothelial cells undergo apoptosis in the
absence of the pro-survival signaling from VEGFR2. Conversely, in the presence of
VEGF continued infiltration of vessels cause the tumor to become hypervascularized.
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Figure 1.2: Pathological Angiogenesis. (1.) The avascular tumor growing off of the
vascular between 1-2mm in size undergoes a (2.) hypoxic switch releasing proangiogenic factors. (3.) Sub sequentially, robust angiogenesis occurs allowing the tumor
to increases in size an all a means for (4.) tumor cell shedding.
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This process leads to a continual supply of nutrients for the growing tumor and cellular
access to the vascular system for transplantation from one part of the body to another,
metastasis.

Furthermore, many tumorigenic cells are not only capable of eliciting

angiogenesis through angiogenic factor release, but themselves utilize angiogenic
receptors signaling to elicit anti-apoptotic phenotypes.

Therefore anti-angiogenic

therapies are widely sought in addition to traditional chemotherapeutics (Bergers et al.,
2008; Holash et al., 2008). There has been mild success in the development of antiVEGF therapies by Regeneron, although further development of effective anti-angiogenic
therapies is hindered by the apparent lack in understanding of the mechanistic roles of the
Tie family receptors in conjunction with their angiopoietin ligands (Augustin et al., 2009;
Yancpoulos et al., 2000).

1.3.1 Tie Family Receptors
The Tie family receptors along with the VEGF receptors are the only known
endothelial cell-specific RTKs. Studies with dominant negative and null mice revealed
the loss of Tie2 function results in embryonic death because due to the failure of the
vasculature system to mature from the primary plexus (Dumont et al., 1994; Sato et al.,
1995). Thus, it was proposed that Tie2 is not required for the differentiation of
endothelial cells from angioblast, but rather for their maintenance and proliferation
(Dumont et al., 1994). Mice lacking TIE1 also die in utero, most likely a result of
pulmonary edema (Puri et al., 1995). Although the vasculature remains intact, the
integrity of vessel endothelial cells is compromised. Accordingly, TIE1 null mice display
defects in vessel integrity demonstrated by localized hemorrhaging and the presence of an
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underdeveloped heart. However, the exact role of Tie1 in angiogenesis remains unknown.
Considerable evidence also identifies the angiopoietins and the Tie2 receptor as
important regulators of tumor-induced angiogenesis and, therefore, cancer growth and
metastasis (Lin et al., 1998; Lin et al., 1997; Oliner et al., 2004).

1.2.2 Tie2 Extra-Cellular Domain Structure
Tie1 and Tie2 are type 1 transmembrane protein receptor tyrosine kinases
(RTKs)(Ward and Dumont, 2002; Yancopoulos et al., 2000).

The two receptors are

remarkably similar sharing 36.7% sequence identity. More over the human, mouse, rat,
and bovine Tie2 receptor is almost identical, sharing 92% sequence identity. Based upon
the sequence of Tie2, the extracellular domain was predicted to contain two
immunoglobin-like (Ig) loops separated by three epidermal growth factor-like (EGF)
repeats, all followed by three tandem fibronectin type III repeats (FNIII) (Dumont et al.,
1993). Further structural analysis revealed by transmission electron micrographs, the
extracellular portion resembled an arrow with the Ig and EGF domains making up the
head and the stalk encompassing the FNIII repeats (MacDonald et al., 2006). Although
binding studies originally identified both the Ig and EGF domains of Tie2 as necessary
and sufficient for angiopoietin binding(Barton et al., 2005; Fiedler et al., 2003), more
recent mutagenesis and crystallographic data revealed the ligand-binding site is with in
the Ig2 domain(Barton et al., 2006).

Furthermore, as depicted in Figure 1.3A the

molecular structure of the Tie2 extracellular domain it was found to contain not two Iglike folds, but three Ig folds. The most striking feature of Tie2 observed in these studies
was the lack in conformational change within the Tie2 receptor in it ligand bound and
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Figure 1.3: Ribbon diagram of the key structural domains of the Tie2 receptor.
(A.) The extracellular domain of the Tie2, PDB 2GY5. The Ig1, Ig2 and Ig3 domains
are color coordinated as red, green, and blue, respectable. Between the Ig2 and Ig3
domains are the tandem EGF1-3 domains colored yellow, purple, and orange,
respectably. (B.) The Tie2 tyrosine kinase domain rotated 90° on the y-axis, PBD 1FVR.
The two conserved lobe domains; N-terminal and C-terminal are colored blue and red,
respectably. The three catalytic loops are labeled and colored yellow. The extended Cterminal tail, containing the substrate tyrosines 1101, 1107, and 1112 is labeled cyan.
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unbound state. These observations tend to lean towards the mode of activation to be
ridged body clustering of the Tie2 receptor by its cognitive angiopoietin ligands.

1.3.2 Tie2 Kinase Domain Structure and Function
In general, receptor tyrosine kinase signaling and activation is initiated by ligand
binding which induces receptor clustering and proximity of the cellular tyrosine kinase
domain. This activation leads to an increase in tyrosine phosphorylation, where upon
multiple tyrosines can be phosphorylated, inducing recruitment of additional complexes,
and initiation of downstream cellular signaling cascades. Determining the structures of
tyrosine kinase domains has illuminated the structural elements that govern their activity
(Johnson et al., 1996).
The structure of the Tie2 TKD has been determined to 2.2Å and not surprisingly
appears to be similar in architecture to others, most notable the fibroblast growth factor
receptor (FGFR) (Shewchuk et al., 2000). In Figure1.3B, a Cα trace of the Tie2 TDK
reveals the presence of the two commonly observed N-terminal and C-terminal lobes
found in virtually all kinases. The N-terminal lobe (residues 808-904) folds into a fivestranded anti-parallel β-sheet. Within the N-terminal lobe are two acidic residues (K855
and E872) and a glycine rich nucleotide binding loop (residues 831-836) responsible for
proper coordination of the substrate α, β, and γ phosphates of ATP. The C-terminal lobe
(residues 905-1124) is primarily α-helical consisting of seven α-helices, four β-strands,
and an extended C-terminal tail. Between the N- and C-terminal lobes is the kinase
active site consisting of the catalytic (residues 962-968) and activation loops (residues
982-1008). The activation loop in Tie2 contains one tyrosine (Y992) and begins with the
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highly conserved sequence Asp-Phe-Gly. The end of the activation loop has single
residue replacement form the conserved sequence, Ala-Phe-Glu, to end with Ala-Ile-Glu.
The sequence of the catalytic loop, containing the catalytic aspartic residue (D964), is
identical to other kinase domains: His-Arg-Asp-Leu-Ala-Ala-Arg-Asn (Hubbard et al.,
1994; Mohammadi et al., 1996; and McTigue et al., 1999).
The C-terminal tail exist in an extended conformation and has three tyrosine
substrate residues: Y1101, Y1107, and Y1112.

Tyrosine phosphorylation serves to

recruit intracellular signaling molecules with Src homology 2 (SH2) or phosphotyrosine
binding (PTB) domains. Specifically, Y1101 has been shown to be the major site of
phosphorylation, recruiting growth factor receptor-bound protein 2, Grb2, and the p85
subunit of phophatidylinositol 3-kinse, PI3-K (Huang et al., 1995; Kontos et al., 1998).
The recruitment of PI3-K initiates cell motility and downstream survival signaling events
through the PKC and Akt pathways, respectably. It has recently been shown that Ang1
treated endothelial cells are capable of initiating either trans Tie2 signaling in cell-cell
junctions or cis Tie2 signaling at cell-substratum junctions (Fukuhara et al., 2008;
Saharinen et al., 2008). At cell-cell junctions, Tie2 signaling is induced by the bridging
of multimeric Ang1 between neighboring cells, leading to a quiescent phenotype.
Primarily through cellular signaling cascades involving the Akt-eNOS pathway.
Conversely, in cells with limited cell-cell contacts the phenotype changes from a resting
to mobile state. This change is reflected in the utilization of Tie2 signaling in cis,
primarily through the PKC-MAPK pathway. Further studies inhibiting the activity of
PI3-K have shown the effect of Y1107 in mediating cell mobility by recruitment of the
downstream-of-kinase-related docking protein, Dok-R (Jones et al., 2003; Master et al.,
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2001). Once phosphorylated, Dok-R is capable of recruiting Nck along with the p21activating kinase, Pak1, restoring cell mobility in a PI3-K independent mechanism.
Phospho-tyrosine 1112 has been reported to be a regulatory mechanism in the recruitment
of a protein tyrosine phosphatase, SH-PTP2 (Huang et al., 1995).

Recruitment of SH-

PTP2 is not fully understood but believed to act as an attenuator to Tie2 signaling by sitespecific phosphate removal.
Tie2 appears similar in architecture to FGFR TKD, although appears to function
slightly different in activation. Sequence alignment and structural overlays of Tie2 TKD
and FGFR TDK reveals a sequence identity of 45% with an rmsd for the C-terminal and
N-terminal lobes of 0.76Å and 0.58Å, respectably (Shewchuk et al., 2000). Activation of
many tyrosine kinase domains is thought to be in trans due to the dimerization or
clustering of the kinase domains by extracellular ligand binding.

Unlike FGFR,

endogenous Tie2 activation requires receptor clustering, although kinase dimerization has
been shown to be sufficient for trans auto-phosphorylation (Kontos et al., 1998; Davis et
al., 2003). Activation typically involves phosphorylation of a tyrosine residue in the
activation loop by base-catalyzed transfer of a γ phosphate from ATP to the hydroxyl
moiety in the tyrosine side chain. As in the case of FGFR TDK, this phosphorylation
leads to a conformation change allowing the phospho-tyrosine to interact with basic
residues, stabilizing the active conformation. Phosphorylation of the active loop leads to
a 100-fold increase in tyrosine kinase activity (Furdui et al., 2006). Conversely, the Tie2
TDK activation loop appears to take on a phospho-tyrosine independent “active
conformation.” Control of auto-phosphorylation for Tie2 appears to lie in the inhibitory
conformation of the ATP coordination residues in the N-terminal lobe. The acidic K and
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E residues are not properly aligned to coordinate ATP as well as nucleotide-binding loop
is in a closed conformation blocking the active site. Furthermore, the x-ray structure of
Tie2 TDK shows the extension of the C-terminal tail into the active site, possibly acting
as a substrate mimic. Fundamentally, deletion of the last 15 residues shows a drastic
increase auto-phosphorylation, as compared to wild type Tie2 (Niu et al., 2002). In
situations with kinase domains that require increases in localization to elicit activation,
control over enzymatic activity may not be as stringent as seen with other kinases that are
always in close proximity (Taylor et al., 1995). As is the case for Tie2, the inhibitory
elements are due to conformations of highly flexible loop regions, typically with high Bfactors.

This leads to the possibility of other proteins that could modulate kinase

phosphorylation. This hypothesis has been further supported by the tight control of an
endothelial specific phosphatase, VE-PTP, on Tie2 phosphorylation and the possibility of
Tie1 as an inhibitory co-receptor (Fachinger et al., 1999).

1.4.1 Angiopoietin Ligand Function
Initially described as an orphan receptor (Dumont et al., 1992), Tie2 was
subsequently shown to interact with all four of the angiopoietins (Ang1-Ang4)(Davis et
al., 1996; Maisonpierre et al., 1997; Valenzuela et al., 1999). The different angiopoietins,
although having high sequence homology, elicit different responses from the receptor
tyrosine kinase Tie2. Loss-of-function and gain-of-function genetic studies in mice have
been beneficial in understanding the physiological effects of Ang1 and -2 on the vascular
system. Mice lacking Ang-1 expression die en utero, displaying the same phenotype of
mice lacking TIE2. Vascular development progresses through vasculogenesis but fails to
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proceed through angiogenesis with a loss of tubular formation in the primary plexus. As
such, the over expression of Ang-1 in mice leads to hypervascularization with many
stabilized branching vesicles, supporting the agonistic mechanism of Ang1 for Tie2 (Suri
et al., 1996). Furthermore, the over expression of Ang1 led to an attenuation of the
chemotatic signaling by VEGF and a decrease in vessel leakiness (Thurston et al., 1999).
The agonistic action of Ang1 on Tie2 signaling appears to be the primary phenotype of
vascular quiescence.
Conversely, Ang2 acts as an antagonist to Tie2 signaling promoting angiogenesis.
Contradictorily to the ANG1 null mouse, ANG2 knockout mice develop past embryonic
angiogenesis but suffer from severe vascular dysmorphogenesis in adulthood causing
mice to die about 2 weeks post birth.

ANG2 null mice are hypervascularized and

resistant to vascular remodeling as seen in the postnatal development of the retinal lens.
Upon birth Ang2 expression is robustly increased in the retinal lens, which undergoes
vascular regression that is obligated in the ANG2 null mouse (Gale et al., 2002).
Furthermore, the expression of Ang2 appears to be up regulated to vascular beds
undergoing angiogenesis. Vessel sprouting relies on proper coordination of Ang2 and the
hypoxia induced release of VEGF. Alternatively, when endothelial cells only receiving
pro-angiogenic signaling from Ang2 the vessel regresses. As such, the over expression
of Ang2 during developmental angiogenesis causes the mice to die en utero, mimicking
the phenotype of the TIE2 and ANG1 null mice (Maisonpierre et al., 1997). Taken
together these observations depict Ang2 as an antagonist of Tie2 signaling in that its
angiogenesic phenotype is to promote vessel permeability making endothelial cells
susceptible to chemotatic signaling.
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Indeed, Ang1 is a constitutive agonist to Tie2 while Ang2 is a context-dependent
one (Davis et al., 1996; Gale et al., 2002; Maisonpierre et al., 1997). The hypothesis that
differential presentation and binding of the various angiopoietins to Tie2 is responsible
for their distinct biological effects appears unlikely in light of previous evidence that
Ang1 and Ang2 bind to the same region of Tie2 (Barton et al., 2005; Barton et al., 2006;
Maisonpierre et al., 1997).
Now, it appears more likely that other cell-specific surface receptors exist that
could help transduce the angiopoietin signals and modulate their functional potential.
This hypothesis was recently supported by several reports defining a potential role for
Tie1 in Tie2 signaling (Kim et al., 2006; Saharinen et al., 2005; Yuan et al., 2007). Tie1,
although a close sequence homologue of Tie2, does not interact directly with the
angiopoietins and its in vivo ligands have yet to be identified (Maisonpierre et al., 1997).
Nevertheless, the angiopoietins may affect Tie1 function (Kim et al., 2006; Saharinen et
al., 2005; Yuan et al., 2007). As observed by co-immunoprecipitation analysis, Tie1 and
Tie2 appear to associate on the cell surface with receptor phosphorylation correlating
with activation. A recent study using catalytically inactive Tie2 demonstrates that Tie1
phosphorylation can occur in trans and is dependent on a functional Tie2 (Kim et al.,
2006; Yuan et al., 2007).

1.4.2 Angiopoietin Structure
The Angiopoietins are a small set of growth factor ligands for the Tie2
endothelial-specific receptor tyrosine kinase. They are unique in that the prototypic
family member, Ang-1, is a Tie2 agonist while the highly homologous Ang-2 is a
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context-dependent agonist. Ang-1 expression is primarily observed in vessel supporting
cells such as smooth muscle cells, pericytes, and fibroblast.

Conversely, Ang-2

expression is primarily observed on endothelial cells and transcriptionally unregulated by
hypoxia, shear stress, and chemotatic response signaling (Augustin et al., 2009). The
primary sequence of the angiopoietins can be divided into three distinct domains with
independent functions. The first ~50 amino acids folds into an angiopoietin specific
super-clustering domain responsible for higher order ligand assembling. Transmission
electron microscopy experiments of Ang-1 and -2 show the amino terminal domain is
responsible for creating a mixture of oligomeric states, with hexameric being the
predominate multimerization state (Dais et al., 2003). In this regard Ang-1 and -2 are
indistinguishable from each other. Following the super clustering domain is ~215 amino
acids which resembles a coiled coil domain, capable of forming ligand dimers. The
remaining ~220 carboxyl terminal amino acids fold into a fibrinogen domain, shown to
interact with the Tie2 extracellular domain (Barton et al., 2005; Barton et al., 2006).
Initial studies by Davis and colleagues identified the receptor-binding fibrinogen domain
as necessary and sufficient for their unique functional activities. Closer examination of
the angiopoietin fibrinogen domain reveals it folds into the three commonly observed A,
B, and P fibrinogens. Binding studies of the Ang-2 to Tie2 revealed the amino acids
responsible for receptor recognition or encompassed in the P-domain (Barton et al., 2005;
Barton et al., 2006). Interestingly the multimerization state of the angiopoietins directly
affected their ability to transduce Tie2 activation in endothelial cells. In their monomeric
forms, Tie2 activation was abrogated.

Pretreatment of endothelial cells with the

monomeric fribinogen domains was capable of competitively inhibiting Tie2 activation
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by higher angiopoietin multimeric states (Davis et al., 2003). More recently, the rational
for higher multimeric states have been proposed in the differential signaling from Tie2 on
two adjacent cells at tight junctions or at none cell junctions; initiating quiescence or
migration, respectably, further supporting the means in which the angiopoietins are
capable to maintaining vascular stability (Saharinen et al., 2008; Fukuhara et al., 2008).
The requirement for multimerized ligand presentation to Tie2 is currently under active
research.
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Chapter 2
Tie1-Tie2 complex formation

2.1 Pre-existent Tie1-Tie2 Complexes Observed By FRET Imaging On The Cell
Surface
To examine the potential role of Tie1 as a co-receptor and evaluate Tie1-Tie2
interactions on the cell surface, we monitored receptor-receptor interactions in vivo by
tagging the individual proteins with CFP and YFP, and following their localization and
association by confocal microscopy coupled with fluorescence (Förster) resonance
energy transfer (FRET). Specifically, for assessing Tie1 and Tie2 receptor spatial
proximity during angiopoietin signaling, we exploit the FRET methodology recently
utilized by the Tsien and Springer groups to analyze the role of lipid modifications in
membrane partitioning and Integrin signaling, respectively (Kim et al., 2003; Zacharias et
al., 2002). As depicted in Figure 2.1, we fused the monomeric enhanced green fluorescent
protein (eGFP) variants mCFP and mYFP to the carboxyl termini of Tie2 and Tie1
respectively in place of the catalytic tyrosine kinase domain. As energy transfer between
donor (mCFP) and acceptor (mYFP) only occurs over short distances (≤ 10nm), emission
of mYFP following excitation of mCFP is observed only when Tie1 and Tie2 are in close
proximity, presumably as a receptor/co-receptor complex. The FRET efficiency is
calculated by subtracting the background FRET (determined by the acceptorphotobleaching method) from the experimental FRET efficiency (Wouters et al., 2001).
Using our FRET-based proximity assay, we clearly observe Tie1-Tie2 association
on the cell surface indicating the two receptors are within less than 100Å of one another
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Figure 2.1: Schematic Representation of the Tie1-Tie2 FRET proximity assay.
Ribbon diagrams of the Tie1 (Blue) and Tie2 (Red) extracellular domains are fused to the
monomeric GFP variants mCFP (Cyan) and mYFP (Yellow), respectably.

As the

receptors come in close proximity to each other, as depicted on the right, upon excitation
of mCFP at 458nm, non-radiative energy transfer occurs to mYFP, resulting in YFP
emission. In the event the receptors distance is >10nm, as depicted on the left, upon
mCFP excitation, no energy transfer to YFP occurs.
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by measuring a FRET effeiciecy and visualized by an increases in mCFP emission after
photo-disruption of mYFP. Interestingly, our observations are in the absence of
angiopoietin ligand, further demonstrating that Tie1 and Tie2 are in a pre-existent
complex prior to ligand recognition. Figure 2.2A-C illustrates a representative image of
the fluorescence intensity and membrane localization of Tie2-CFP/Tie1-YFP, which we
will denote as wild-type for our discussions. Both receptors localize with uniform diffuse
staining predominantly on the plasma membrane. Using the acceptor-photobleaching
technique for measuring FRET efficiency, we observed Tie1-Tie2 association with an
average overall efficiency of 30%, 27%, and 19% under optimal conditions in HEK293,
U2OS, and EA.hy 926 cells, respectively. In accordance with the variables identified by
Springer and colleagues (Kim et al., 2003), the length of linker between the receptor
transmembrane domain and amino-terminus of the fluorescent protein was varied to
identify the optimal combination of receptor length, and fluorophore-receptor pair (data
not shown). Furthermore, for our experiments, HEK293 and U2OS cells were chosen in
addition to EA.hy 926 endothelial cells, based upon their lack of endogenous Tie
receptors as well as ease of transfection and cellular imaging (Yuan et al., 2007).
We found, as expected, that increased linker lengths significantly decreased
overall FRET efficiency (Kim et al., 2003). Among several constructs tested, one pair
with eleven and ten residues for Tie1 and -2 respectively, within the linker, consistently
yielded reliable results in all three independent cell lines (EA.hy 926, HEK293, and
U2OS). Importantly, both CFP and YFP variants carry the A206K, L221K, and F223R
mutations thought to significantly decrease the chance of fluorescent protein
multimerization (Zheng et al., 2002). As a control, we have also co-expressed each
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Figure 2.2: In vivo FRET imaging of Tie1-YFP and Tie2-CFP on the cell surface.
HEK293 (A), U2OS (B), and EaHy.926 (C) cells were transiently transfected with the
chimeric Tie2-CFP (cyan) and Tie1-YFP (yellow) receptors.

Cellular fluorescences

images for CFP and YFP were acquired prior to and post acceptor photobleaching.
FRET efficiency was calculated within the region of interest (green box) and depicted in
an absolute range from high (red-1.0) to low (purple-0.0) as a colorimetric overlay image.
Light gray bar in each image indicates 10 µm.
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Figure 2.3: In vivo FRET imaging of chimeric PlexinA1 receptors co-expressed with
chimeric Tie1 and -2 receptors.

HEK293 cells co-transfected with (A) Tie2-CFP

(cyan) and PlexinA1-YFP (yellow) or (B) PlexinA1-CFP (cyan) with Tie1-YFP (yellow).
Cellular fluorescences images for CFP and YFP were acquired prior to and post acceptor
photobleaching. FRET efficiency was calculated within the region of interest (green box)
and depicted in an absolute range from high (red-1.0) to low (purple-0.0) as a
colorimetric overlay image. Light gray bar in each image indicates 10 µm.
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Figure 2.4: Graphical representation of average FRET efficiencies for combinations
of Tie receptors and plexinA1 controls in different cell lines. The date is represented
as mean +/- SEM.
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receptor with both fluorophores to account for any non-specific interactions that may
occur between the tagged fluorescent proteins (Zacharias et al., 2002). No FRET signal is
observed under these circumstances (data not shown). Similarly, to evaluate possible
effects of over-expression, Tie receptors were co-expressed with the functionally
unrelated receptor plexin-A1 (both mCFP and mYFP variants). As seen in Figure 2.3,
under these circumstances we observed between 0 and 2% FRET efficiency. The five
experimental conditions are graphically compared in Figure 2.4. Together, these findings
validate the overall specificity of the FRET proximity assay and that that protein
overexpression and nonspecific interactions between the fluorescent proteins does not
contribute significantly to the observed FRET efficiency. Interestingly, the proximity
assay allowed us to visualize in vivo the association of a Tie1-Tie2 co-receptor complex
within both epithelial and endothelial cell lines.

From this observation we further

hypothesized the interaction is mediated by the receptors extra-cellular domains.

2.2 Identification Of Residues Involved In Tie1-Tie2 Interactions
To understand the potential structural differences between Tie1 and Tie2 that
mediate their distinct biological properties and identify structural elements that may
contribute to Tie1-Tie2 interactions, we modeled the structure of Tie1 using the
experimentally-determined 2.5Å Tie2 structure (Barton et al., 2006) and the program
MODELLER (Marti-Renom et al., 2000). Tie1 and Tie2 are highly homologous –
sharing 39% amino acid identity – and, not surprisingly Tie1 can be easily modeled on
the structure of Tie2. A schematic representation of the molecular surfaces of Tie2 and
of the Tie1 model, color coded according to electrostatic potential and hydrophobicity of
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the exposed amino acid side chains, is presented in Figure 2.5. The hydrophobic surface
features of Tie2 and Tie1 are very similar overall. Interestingly, two patches of exposed
hydrophobic residues, indicated with arrows, are present at the tip of Tie2, but are absent
in the equivalent Tie1 region. Indeed, these overlap with the binding site of the Tie2specific ligand Angiopoietin-2 (Ang2) indicated with a green circle(Barton et al., 2006),
providing the structural explanation for the distinct ligand-binding properties of the two
Tie receptors.
More importantly, comparison of the surface electrostatic potentials of Tie1 and
Tie2 as seen in Figure 2.5C and D reveals that Tie2 has a slight negative overall charge
with a theoretical pI value, if isolated in solution, of 6.9. Tie1, on the other hand has a
positive overall charge with a corresponding pI value of 9.3. Tie2 has one expansive
negatively-charged surface area, which results from the approximation of several exposed
aspartic and glutamic acids in the Ig1 and EGF1 domains, including D25, E53, D60,
E109, D236, D239, D252 and D283 (Figure 2.5C, right).

The corresponding Tie1

surface area if Ig1 and EGF1 is overall neutral in charge. Tie1, on the other hand,
contains one large positively charged area on its surface, located on the opposite side of
the molecule (Figure 2.5D, left). Its electrostatic surface potential results from the
approximation of several arginines and lysines in Ig1, EGF2, and Ig3, including R38,
R82, K95, R91, R260, R279, R263, R349, R388, R427, R437, and R438.
The presence of large patches of oppositely charged molecular surfaces in Tie1
and Tie2 suggest that these areas might be involved in Tie1-Tie2 recognition.

To

evaluate their roles in mediating receptor-receptor interactions, we utilized site-directed
mutagenesis in combination with our Tie1-Tie2 FRET proximity assay. Various regions
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Figure 2.5: Extracellular surface feature comparisons of the experientially
determined Tie2 and the modeled Tie1 structure. The left and right panels are related
by 180o rotation about the y-axis. (A) The hydrophobicity surface rendering of Tie2 and
Tie1, with the hydrophobic side chains colored green and the hydrolytic side chains in
grey. Arrows point to the previously determined ligand-binding region within the tip of
the second immunoglobulin domain in Tie2.

(B) Color-coded electrostatic surface

potential of Tie1 and Tie2 with Red and blue represent electrostatic potentials in the
range of –11 to +11 kBT, where kB is the Boltzman constant and T is the temperature (293
K). Amino acids responsible for the ionic interface are labeled by their single letter code
and position.

33

A.

B.

34
within the charged patches were targeted by mutagenesis through the construction of Tie
variants containing multiple amino acid substitutions and analyzed for their ability to
associate via FRET. Our experience has shown that single site mutations often have little
or no effect on interactions involving relatively large protein-protein interfaces (Barton et
al., 2003; Barton et al., 2005; Barton et al., 2006). Therefore multiple mutations within
the charged surface were simultaneously made following a charge reversal strategy,
replacing basic residues with acidic amino acids and vice versa. A list of all the point
mutations is schematically represented in Figure 2.6. All of these charge reversal
mutations are in surface exposed residues; as such, we expect the mutations will not
affect the overall folding of the proteins. In agreement, upon transfection into HEK293
cell, all mutant receptors are well expressed, processed, and localize correctly to the cell
surface. Representative images of the mutant receptors can be seen in Figure 2.7A and B.
Using the FRET proximity assay to evaluate the ability of the mutant Tie
receptors to interact with the corresponding wild type Tie receptor, it is clear we have
identified several charged surface residues involved in their association. Three of the four
Tie1 mutants (B1, C1, D1) and all three Tie2 variants (A2, B2, C2) exhibit significantly
lower FRET efficiencies than the pairing of wild-type receptors. A representative image
of the receptor pair mut-B1-Tie1-YFP/wild-type-Tie2-CFP, is displayed in Figure 2.7A.
Even under ideal conditions, we failed to observe significant FRET when these two
receptors are co-expressed in either HEK293 or U2OS cell lines (0% FRET efficiency).
Similarly, mut-A2-Tie2-CFP exhibits proper localization to the membrane, yet fails to
associate with wild-type-Tie1-YFP to any significant extent (5% FRET efficiency Figure 2.7B). Together, the data suggest a complex interaction between Tie1 and Tie2
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Figure 2.6: Molecular surface representation of Tie2 and modeled Tie1 structure
color-coded according to their corresponding mutations. (A) The amino acids
mutated in Tie1 are colored in blue: A1: Tie1(K95E, R260E, R263E), B1: Tie1(R260E,
R437E, R438E), C1: Tie1(R437E, R438E), D1: Tie1(R91E, K95E, R427E). (B) The
corresponding acidic interface mutations in Tie2 are labeled red: A2: Tie2(E53K,
D236K, E239K), B2: Tie2(E53K, D60K, D389K), and C2: Tie2(E53K, D60K, E109K,
D236K, E239K, D389K).
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Figure 2.7: In vivo FRET imaging of the mutant Tie receptors co-expressed with a
corresponding wild type Tie receptor. Co-expression in HEK293 cells of (A) wild type
Tie2-CFP (cyan) with mutant B1(R260E, R437E, R438E)-Tie1-YFP (yellow) and (B)
mutant A2(E53K, D236K, E239K)-Tie2 CFP with the corresponding wild type Tie1-YFP
receptors. Cellular fluorescences images for CFP and YFP were acquired prior to and
post acceptor photobleaching. FRET efficiency was calculated within the region of
interest (green box) and depicted in an absolute range from high (red-1.0) to low (purple0.0) as a colorimetric overlay image. Light gray bar in each image indicates 10 µm.
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Figure 2.8: Graphical representation of average FRET efficiencies for combinations
of wild type Tie receptors to the corresponding mutant Tie receptors in HEK293
cells. The date is represented as mean +/- SEM.
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involving a broad surface area within their basic and acidic regions, respectively. Indeed,
several different mutant receptor combinations with a wild-type co-receptor result in the
loss of receptor-receptor association as illustrated by low or absent FRET efficiencies,
demonstrating that the charged surface patches play a role in the Tie1-Tie2 association
(Figures 2.8). Moreover, analysis of the Tie1 mutants suggests that residues R437 and
R438 in the Ig3 domain play a central role in receptor association (compare mutants A1,
B1, and C1 in Figure 2.8). Finally, the identification of mutant-wild-type receptor pairs
that fail to demonstrate appreciable FRET further demonstrates the exquisite specificity
of this proximity assay.

2.3 Tie1 And Tie2 Interactions Are Direct
To validate the notion that Tie1-Tie2 interactions are direct, and not mediated by
an unidentified binding partner, we assayed for receptor complementation - as illustrated
by the restoration of wild-type FRET efficiencies - between two individual mutant
receptors. HEK293 cells were cotransfected with all nine possible combinations of
mutant Tie1 and Tie2 receptors. Given the size and complexity of the potential interface
involved, only a subset of receptor combinations would be predicted to have molecular
surfaces of sufficient complementarity to rescue the FRET efficiency to near wild-type
levels. Indeed, from all tested receptor combinations we identified only two mutant
receptor pairs; mut-B1-Tie1-YFP/mut-C2-Tie2-CFP, and mut-C1-Tie1-YFP/mut-A2Tie2-CFP, which display significant receptor association. Representative FRET
efficiencies for each mutant receptor pair are shown in Figure 2.9. Individually, each of
these mutated receptors is incapable of interacting with their counterpart wild-type
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Figure 2.9: Tie1 and Tie2 form a direct interaction as demonstrated by allelic
suppression. HEK293 cells were co-transfected with the following mutant receptor pairs
(A) mutant B1(R260E, R437E, R438E) Tie1-YFP (yellow) and mutant C2(E53K, D60K,
E109K, D236K, E239K, D389K) Tie2-CFP (cyan) or (B) mutant C1(R437E, R438E)
Tie1-YFP and mutant A2(E53K, D236K, E239K) Tie2-CFP. Cellular fluorescences
images for CFP and YFP were acquired prior to and post acceptor photobleaching.
FRET efficiency was calculated within the region of interest (green box) and depicted in
an absolute range from high (red-1.0) to low (purple-0.0) as a colorimetric overlay image.
Light gray bar in each image indicates 10 µm.
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Figure 2.10: Graphical representation of average FRET efficiencies for pairs of
mutant Tie1-Tie2 receptors demonstrating allelic suppression.
represented as mean +/- SEM.

The date is
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receptor or other corresponding mutant receptors, yet when co-expressed, display FRET
efficiencies nearly identical to that of wild-type receptors (Figure 2.9 and 2.10).
Averaged FRET efficiencies from several independent experiments for each receptor pair
are graphed and compared to wild-type in Figure 2.10. FRET efficiencies between wildtype receptors and the two mutant pairs are not statistically different. This demonstration
of “allelic suppression” excludes the possibility of an unknown binding partner, and
provides strong support for a direct interaction between Tie1 and Tie2 involving the
complementary charged surface areas within the receptor ectodomains.

2.4 Conclusions
Understanding the precise role of Tie1 in angiopoietin Tie signaling has been
controversial since its discovery 15 years ago. Furthermore, identifying Tie1 as a coreceptor to Tie2 is still under much scrutiny. Using a powerful in vivo proximity assay,
we have begun to identify a role for Tie1 in Tie2 signaling by demonstrating a direct
interaction between these receptors. We further identify, via structure-based site-directed
mutagenesis, the precise molecular surface regions of the Tie1 and Tie2 ectodomains,
which mediate this critical interaction.
The utility of the FRET proximity assay allowed us to monitor the interaction in
real time between Tie1 and Tie2 on the cell surface. Upon co-expression Tie1 directly
interacts with Tie2 primarily through ionic interactions with in the extra-cellular domains.
This observed interaction between Tie1 and Tie2 is supported by other groups in the
ability to co-IP out of crude HUVEC lysate the heterogeneous receptor complex in the
absence of angiopoietin stimulation (Saharinen P. et al., 2005 and Kim L.K. et al., 2006).
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Most interestingly, previous attempts to co-IP Tie1 with Tie2 were dependent on
stringent

cross-linking

with

DTSSP

of

cellular

proteins.

Typically

most

immunoprecipitations are performed with stringent washing of protein-coupled sepharose
beads, capable of disrupting weak protein-protein interactions. As seen in the molecular
surface charge rendering of Tie1 and Tie2, the interaction between the receptors is
primarily ionic and not hydrophobic. Furthermore, disrupting this interaction required
only a small set of clustering point mutations within the co-receptor interface. These
observations indicate the hetero receptor complex has adopted its minimum energy state;
only a small amount of energy is required to disrupt Tie1 from interacting with Tie2. As
such, we further hypothesize the angiopoietins have different properties affecting the
Tie1-Tie2 hetero receptor complex.
It is interesting to note the interaction between Tie1 and Tie2 differs from others
(Macdonald et al., 2006). Using Tie1 truncation mutants and a TrkA/Tie2 fusion protein,
Marron and colleagues, for example, suggest an association between Tie1 and Tie2 that is
mediated by their cytoplasmic kinase domains (Marron et al., 2000), while we observe a
dynamic interaction between these receptors in the absence of the catalytic kinase
domains and any subsequent down-stream signaling events. Moreover, our structurebased receptor mutagenesis, combined with localization and FRET analysis strongly
supports receptor interactions through their extracellular domains. Interestingly, despite
having documented receptor association, Marron and colleagues did not observe
significant phosphorylation of Tie1 (Marron et al., 2000). However, during the course of
Tie2 activation, others have observed Tie1 phosphorylation (Saharinen et al., 2005; Yuan
et al., 2007). It appears in some circumstances Tie1 phosphorylation correlates with Tie2
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activation, although it remains unknown if this is as a result of stable or of transient
interactions caused by high local concentrations of Tie2, i.e. within signaling clusters
(Milner et al., 2008; Saharinen et al., 2005). Furthermore, the physiological significance
of Tie1 phosphorylation remains unknown.

2.5 Methods
2.5.1 Cloning and Gene Expression
The sequences encoding the human Tie1 (IMAGE 5767075) and Tie2 (IMAGE
5228999) genes were cloned as interchangeable receptor-fluorophore fusion cassettes in
both pcDNA3.1(+) hygromycin and neomycin resistance vectors for expression in human
embryonic kidney 293 cells and human osteosarcoma cell line U2OS. Briefly, NheI and
EcoRI sites were appended to the amino and carboxy-terminus via PCR using the
following

oligonucleotides:

Tie1-Nhe;gctagcATGgtctggcgggtgccc,

Tie2-Nhe;

gctagcATGgactctttagccagcttag, Tie1-EcoR1; gaattcggtgcgtctccgatgcaggcagc and Tie2EcoRI; gaattctctcctttgcacatttgccctc (restriction sites are underlined and initiating
methionine is in capital letters). After insertion of receptor DNA into the pcDNA vectors,
GFP cassettes were cloned down-stream and in-frame with EcoRI and XhoI yielding an
open reading frame consisting of Tie receptor fused to either C- or YFP. Monomeric CFP
and YFP variants (containing dimeric suppression mutations-obtained from Dr Timothy
Springer) were utilized as templates for fluorophore incorporation via PCR using the
following oligonucleotides; C/YFP-EcoRI; gaattcatggtgagcaagggcgaggag, C/YFP-XhoI;
ctcgagttatctagatccggtggatcc. Although several initial constructs were constructed and
tested for optimal linker length between receptor and fluorophore, ultimately, one
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receptor pair was chosen for further study in which the Tie receptors were fused to either
CFP or YFP after residues 796 and 780 of Tie1 and Tie2 respectively, leaving the
transmembrane domain intact as well as ten or eleven additional cytoplasmic residues,
but eliminating the carboxyl-terminal tyrosine kinase catalytic domain. Altering
fluorophores on individual receptors did not appear to make any significant difference
and were, therefore, used interchangeably. Mutations within Tie1 and Tie2 coding
regions were introduced by site directed mutagenesis (Quikchange Multi, Stratagene)
following manufacturers recommendations. To confirm the presence of the desired
mutations, both DNA strands were sequenced using standard di-deoxy sequencing
chemistry (Cornell University Bioresource Center).

2.5.2 Cell Manipulations and Transfections
HEK293, U2OS, and EA.hy 926 (a gift from Dr Cora-Jean Edgell) cells were
grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum, 100U/mL
penicillin, and 100 µg/mL streptomycin. Cells were consistently transfected at 80-90%
confluence in 35mm glass bottom culture dishes (MatTek) using Lipofectamine 2000
(HEK293) or FuGENE HD (U2OS) or FuGENE 6 (EA.hy 926) according to
manufacturer’s

recommendations

(Invitrogen

and

Roche).

For

co-expression

experiments, equimolar concentrations of Tie1 and Tie2 vector DNA were used.

2.5.3 Cellular Imaging
The spatial proximity assay was based upon the work of Dr Roger Tsien
(Zacharias et al., 2002) and Dr Timothy Springer and colleagues(Kim et al., 2003). Live
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cell imaging was performed 24-48 hour post-transfection on a Leica TCS-SP2 AOBS
confocal laser scanning microscope equipped with blue diode (405nm), Argon (458, 476,
488, 514nm). green HeNe (543nm), orange HeNe (594nm), and red HeNe (633nm)
lasers, an HCX PI Apo 63x/1.3 n.a. glycerin-immersion objective lens, a motorized XY
stage (Märzhäuser), and an environmentally controlled (temperature, humidity, and CO2)
stage incubator (PeCon). Fluorophore-receptor fusions were imaged using excitation and
emission wavelengths of 458nm and 514 nm for CFP and YFP respectively and
fluorescence emissions were detected with SP window settings of 465-505nm and 525600nm (for CFP and YFP, respectively). The AOTF’s for 458nm and 514nm were set to
92% and 19% respectably to eliminate cross talk between the two SP window channels.
FRET efficiencies were determined using the acceptor photobleaching methodology
using Leica software (ver. 2.61). Briefly, regions of interest were chosen for analysis
based on extent of fluorophore expression, localization, and uniformity. For acceptor
photobleaching, YFP within the region of interest (ROI-green box within images) was
consistently photobleached (with the AOTF ramped up to 100% transmission of the
514nm laser line) from 50% to 70% reduction in fluorescence intensity as monitored by
Leica software. Care was taken to exclude cells for analysis that displayed significantly
higher, or lower, fluorescent intensity than the “average” cell. To eliminate bias, cells
were also chosen based on similar levels of CFP and YFP fusion protein. Similar to the
work by Kim et al. (Kim et al., 2003), cells that displayed significant drift in the x-y focal
plane were discarded for FRET analysis. Due to significant cellular drift, discrete regions,
rather than whole cells were subjected to photobleaching to accelerate FRET analysis.
Pre- and post-bleach images were recorded for both donor (CFP) and acceptor (YFP) and
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FRET efficiency was calculated as: FRETEff=(Dpost-Dpre)/Dpost for all Dpost > Dpre where
Dpre and Dpost is the donor intensity before and after photobleaching respectively. JMP
Software (SAS) was used for all statistical analysis.

2.5.4 Homology model of Tie1
The Tie1 homology structure was modeled using the program MODELLER
(Marti-Renom et al., 2000) and the experimentally determined 2.5Å Tie2 ligand-binding
domain crystal structure (PDB 2GY5) (Barton et al., 2006). Although initial alignments
between Tie1 and Tie2 were prepared using CLUSTALX (Larkin et al., 2007), use of the
sequence/secondary structure alignment implementation in MODELLER yielded better
results and was therefore adopted for final calculations. Four distinct models were
calculated which satisfied basic spatial and stereochemical restraints, however, the model
used for interpretation and illustration purposes had the lowest discrete optimized protein
energy (DOPE) assessment score and MODELLER objective function (Shen and Sali,
2006). Stereochemical analysis via PROCHECK (CCP4, 1994) revealed main chain
parameters better than or within the typical range of values for experimentally determined
protein structures at 2.5Å resolution.
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Chapter 3
Modulating the Tie1-Tie2 Complex by the Angiopoietins

3.1 Different Angiopoietins Differentially Modulate The Tie1-Tie2 Interaction
Despite the high level of sequence identity between Tie2 and Tie1, only Tie2 can
form high-affinity complexes with all four known angiopoietins, while Tie1 does not
bind any of them (Davis et al., 2003; Ramsauer and D'Amore, 2002). As described in
chapter2 with the identification of pre-existing Tie1-Tie2 complex, suggests that Tie1
plays a role in angiopoietin Tie2 signaling. Interestingly, our crystal structure of Tie2
bound to Ang2 (Barton et al., 2006) and to Ang1 show that all angiopoietins bind Tie2 in
a similar conformation, excluding the possibility of differential Tie2 activation resulting
from alternate Tie2/angiopoietin structural arrangements. However, our structural
analysis does suggest that the different angiopoietin ligands could present distinct
molecular surfaces outside of the receptor-binding interface that could influence the Tie1Tie2 receptor complexes (Barton et al., 2005). Based upon our findings we hypothesized
that the observed direct Tie2/Tie1 interactions are inhibitory and the ability, or inability,
of individual angiopoietins to effectively destabilize the Tie1/Tie2 complexes at the cell
surface would define their respective agonistic or antagonistic roles.
To assess the role of Tie1 in Tie2 clustering and activation following angiopoietin
exposure, receptor association, localization, and activation was monitored in the presence
of Angiopoietin-1 or -2. Specifically, Tie1-CFP and Tie2-YFP were expressed in U2OS
and EA.hy 926 cells and stimulated with varying concentrations of Angiopoietin-1 or –2,
and followed by confocal microscopy over the course of 30 or 60 minutes. As shown in
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to that observed for Ang-1. Therefore, our data demonstrates a unique difference between
individual angiopoietins to affect Tie1 –Tie2 association and subsequent Tie2 clustering.

3.2 Tie1 is an Inhibitory Co-Receptor
To further assess the physiological role of Tie1, particularly with its capability to
manipulate Tie2 activation, we followed Tie2 phosphorylation in the presence or absence
of Tie1 and Angiopoietin in both HEK293, and HUVEC’s. Initially, HEK293 cells,
which lack endogenous Tie receptors, were transiently transfected with full-length myctagged Tie2, full-length HA-tagged Tie1, Tie1-CFP lacking a tyrosine kinase domain, or
a combination of the three. As seen in Figure 3.5, western blotting of whole cell lysates
with anti-Tie1 and anti-Tie2 antibodies, respectively, clearly demonstrate robust Tie1 and
Tie2 expression. Interestingly, ectopically expressed Tie2 displays a low level of basal
activation in 293 cells as observed by the anti-phosphotyrosine 992 Tie2 antibody.
However, addition of Tie1 dramatically decreased Tie2 basal activation by ~50%, relative
to Tie2 alone. Interestingly, addition of the chimeric Tie1-CFP, lacking an intracellular
tyrosine kinase domain, also decreases Tie2 activation to levels comparable to those
observed with full-length Tie1. This finding further demonstrates that Tie ectodomain
interactions are necessary and sufficient to attenuate Tie2 phosphorylation.
Using an alternative approach to examine the role of endogenous Tie1, HUVEC’s
were infected with recombinant lentivirus encoding a non-specific (control) or Tie1specific miR-shRNA. A Stable cell lines were selected with puromycin and knock down
of Tie1 receptor expression was determined to be ~70% by western blotting (Figure 3.6).
Sub sequentially, Tie2 receptor activation was analyzed following Ang-1 or Ang-2
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Figure 3.1A, addition of Ang1 to the culture media led to a drastic reduction of Tie1-Tie2
association in U2OS cells within 10 minutes as measured by a loss in FRET between
CFP and YFP. This timeframe corresponds to previously determined rates of Tie2
activation (Bogdanovic et al., 2006; Yuan et al., 2007). Furthermore, the loss in FRET
signal was followed by a dramatic change in Tie2 localization after 20 minutes of
incubation. Specifically, the majority of the membrane-associated Tie2 migrates and
forms discrete foci, reminiscent of the Tie2 punctate staining observed by others in
human lung microvascular endothelial cells (Fukuhara et al., 2008; Saharinen et al.,
2008). Thirty minutes post Ang1 addition cells that contain discrete Tie2 foci are still
observed. As expected from our FRET analysis, Tie1 localization remains undisturbed
following Ang-1 stimulation. EA.hy 926 endothelial cells under similar conditions
behave correspondingly. In these cells Tie2 readily localizes to the membrane, yet
transforms to punctate staining with similar kinetics to HEK293 cells upon addition of
Ang-1 (Figure 3.2). FRET efficiency rapidly decreases (from 19% to 3%) further
demonstrating disruption of Tie1-Tie2 interactions.
Alternatively, when Tie1 and Tie2 are co-expressing in U2OS or EA.hy 926 cells
and treated with similar concentrations of Ang-2, no changes in the Tie1-Tie2 association
and/or Tie2 localization are observed (Figure 3.1B). FRET efficiencies and receptor
localization do not significantly change over a thirty-minute period as graphically
illustrated in Figure 3.3. This is in sharp contrast with the ability of Ang-2 to induce
changes in Tie2 localization in the absence of Tie1, as seen in Figure 3.4. Under these
conditions, Tie2 localization changes to punctate staining within 10-20 minutes, identical
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Figure 3.1: Ang-1, not Ang2, promotes Tie2 clustering from the Tie1-Tie2 coreceptor complex. U2OS cells were transfected with both Tie2-YFP and Tie1-CFP and
monitored by confocal microscopy over a period of 30 minutes. At time=0, 500ng/ml of
(A) Ang-1 or (B) Ang-2 was added to the growth media. Listed below each
representative image are averaged FRET efficiency values correlating to the listed time
point. Arrowheads indicate regions of clustered Tie2. Light gray bar in each image
indicates 10 µm.
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Figure 3.2: Effect of Ang1 and Ang2 on the Tie1-Tie2 co-receptor complex in Ea.hy
926 cells. EA.hy 926 cells were transfected with both Tie2-YFP and Tie1-CFP and
monitored by confocal microscopy over a period of 30 minutes. At time=0, either
500ng/ml of Ang-1 (middle panels), or 500 ng/ml of Ang-2 (right panels) was added to
the growth media. Listed below each representative image are averaged FRET efficiency
values correlating to the listed time point. Arrows indicate regions of clustered Tie2.
Light gray bar in each image indicates 10 µm.
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Figure 3.3: Graphical representation of the average FRET efficiencies between Tie1
and Tie2 after the addition of Ang1 or Ang2. Green and Orange lines represent Ang1,
or Ang2 addition for U2OS cells, respectively, while closed Green circles and closed
Orange squares represent Ang1, or Ang2 addition for EA.hy 926 cells, respectively. Data
are represented as mean +/- SEM.
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Figure 3.4: Ang2 inducing Tie2 clustering in the absence of Tie1. U2OS cells were
singly transfected with Tie2-YFP and monitored by confocal microscopy over a period of
30 minutes following addition of 500 ng/ml of Ang-2 to the growth media. Light gray bar
in each image indicates 10 µm.
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Figure 3.5: Tie1 extracellular is sufficient for attenuating Tie2 phosphorylation.
HEK293 cells were transfected with full-length Tie2-myc alone or in combination with
full-length Tie1-HA, or Tie1-CFP, harvested and lysates probed with anti-Tie1, antiTie2, and anti-phosphotyrosine 992 Tie2. The relative ratio of phosphorylated Tie2 (top
panel) to total Tie2 (middle panel) was determined and the calculated value was
arbitrarily set equal to 1.0 for Tie2 expressed alone. Values are graphically displayed
below each respective lane, representative of 3 independent experiments. *Samples are
from non-adjacent lanes of the same blot.
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Figure 3.6: Tie1 shRNA knockdown sensitizes Tie2 to Ang1 and Ang2. Human
umbilical vein endothelial cells were infected with an shRNA control or Tie1 knockdown
lentivirus and selected with puromycin for stable integration. Asynchronous cultures
were subjected to four hours of serum withdrawal, followed by stimulation with vehicle
(buffer), 500ng/ml Angiopoietin-1, or 500ng/ml Angiopoietin-2. Fifteen minutes
following addition of ligand, cells were harvested and subjected to western blotting with
anti-Tie2 (middle panel), anti-Tie1 (bottom panel), and the phosphotyrosine specific antiTie2 (992) (top panel), as indicated. The relative ratio of phosphorylated Tie2 (top panel)
over total Tie2 (middle panel) was determined and the calculated value was arbitrarily set
equal to 1.0 for unstimulated Tie2 from shControl cells. Values are graphically displayed
below each respective lane, representative of 3 independent experiments.
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addition by means of western blot analysis. In the shRNA control cell line, which
displays wild-type levels of Tie1, Tie2 activation can be readily observed within 15
minutes following the addition of Ang-1 (Figure 3.6). In contrast, and in agreement with
other reports, addition of Ang-2 to the control cell lines fails to significantly alter receptor
phosphorylation and activation (Davis et al., 2003; Maisonpierre et al., 1997).
Alternatively, HUVEC Tie1-shRNA stable cell lines, which expresses
significantly less Tie1 as seen in control cells, behave considerably different. In the
absence Tie1, and in agreement with our findings in epithelial cells, Tie2 displays
approximately 2 fold greater basal activation than within control cells (Figure 3.6).
Furthermore, despite the observation that Tie2 appears partially active in Tie1 silenced
cells, addition of Ang-1 also leads to ~3.5 fold greater receptor activation. However, in
the absence of Tie1, Ang-2 is now also capable of stimulating Tie2 activation. Indeed,
despite the observation that Tie2 appears partially active in Tie1 silenced cells, addition
of Ang-1 or Ang-2 leads to greater receptor activation (~3.5 and 2 fold, respectively).
Cumulatively, these observations are consistent with an inhibitory role for endogenous
Tie1 and indicate its presence is necessary to distinguish the agonist/antagonist role for
Ang-2.

3.3 The Tie2 Kinase Domain is Unnecessary for Receptor Clustering and Tie1
Interaction
Despite a clear demonstration of Tie receptor ectodomain interactions by FRET
analysis, it remained unclear if the intracellular kinase domain could influence receptor
localization and clustering in response to ligand. Therefore, to evaluate the role of the
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Figure 3.7: Tie1 is able to block Tie2 clustering by Ang2, but not Ang1. (A) Control
(top panels) or Tie1 knockdown (bottom panels) stable EA.hy 926 cells were transiently
transfected with full-length Tie2 fused to mCherry and imaged via confocal microscopy
forty-eight hours post transfection. Cells were stimulated with 500ng/mL of
Angiopoietin-1 or -2 and mCherry expression was followed over the course of sixty
minutes. GFP expression (green) indicates stable viral integration and was overlaid onto
mCherry (red) for orientation purposes. Arrows indicate areas of punctate Tie2 staining.
Light gray bar in each image indicates 10 µm. (B) Crude cell lysates were analyzed by
western blot for total Tie1 and Tie2 protein in control and Tie1 knockdown cell lines.
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Tie2 tyrosine kinase domain in Tie interactions, a full-length version of Tie2 with a
carboxyl terminal mCherry domain was transfected into control and Tie1 silenced EA.hy
926 cells.

Similar to the HUVEC Tie1 knockdown experiments, the recombinant

lentivirus was also capable of attenuating Tie1 expression (Figure 3.7B). Under these
conditions, endogenous Tie1 will interact with, and influence Tie2-mCherry localization,
if indeed the tyrosine kinase domains are essential. Accordingly, Tie2-mCherry
localization was monitored by confocal microscopy following both Angiopoietin-1 and -2
addition. Figure 3.7A includes images of cells prior to, 30, and 60 minutes post ligand
addition. As observed with Tie2-YFP chimeras lacking the tyrosine kinase domain
(Figure 3.1A and 3.2), full-length Tie2-mCherry exhibits punctate staining within 30
minutes in the presence of Ang-1 in both control and Tie1 silenced cells. Similarly, Tie2
clustering is observed within 60 minutes addition of Ang-2 in the absence of Tie1. A
slight difference in time between the observed clustering in Ang-1 and -2 induced cells is
likely due to the residual Tie1 (~25% of wild-type levels) that remains in Tie1
knockdown cells. Although these studies do not rule out other potential roles for the Tie
tyrosine kinase domains, these findings demonstrate that kinase domain interactions do
not significantly influence the clustering and localization of Tie2.

3.4 Conclusions
Until now, the molecular basis for the Tie1 and the differential angiopoietin
functions has remained elusive. We have now identified a clear role for Tie1 in Tie2
signaling, and demonstrate a direct, inhibitory interaction between these receptors. We
reveal that this interaction is dynamic and differentially modulated by the different
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angiopoietin ligands thereby providing a molecular mechanism for the observed
differences in angiopoietin function.
Based upon previous studies and the data presented here, we propose a model for
Tie2 signaling as illustrated in Figure 3.8. Specifically, in cells expressing both Tie1 and
Tie2, the receptors form heterodimers within endothelial cells via ectodomain
electrostatic interactions that inhibit Tie2 activation and clustering. Binding of
Angiopoietin-1 to Tie2 promotes heterodimer dissociation, Tie2 clustering, and signaling
initiation.

On the contrary, Angiopoietin-2, is unable to dissociate the inhibitory

Tie2/Tie1 complexes upon binding Tie2 and, therefore, does not induce Tie2 clustering
and signaling, yet behaves as a competitive antagonist by blocking further binding of
Ang-1. Alternatively, for cells that do not express Tie1, all angiopoietins promote Tie2
clustering and activation. Our model explicitly proposes that the balance of Tie1 and Tie2
expression modulates the functional potential of Angiopoietin-2, and by analogy,
vascular homeostasis.
While it is known that Tie2 is expressed ubiquitously throughout the vascular
endothelium (Dumont et al., 1994; Dumont et al., 1992), Tie1 expression is significantly
restricted to vascular bifurcations and branching points following embryogenesis (Porat
et al., 2004). Furthermore, Tie1 is transcriptionally up-regulated by hypoxia, VEGF
stimulation, and in areas of wound healing and tumor growth and development (i.e. sites
of neovascularization) (Korhonen et al., 1992; McCarthy et al., 1998). Therefore, the
adult vasculature is composed of regions of alternating (high and low, or absent) Tie1
expression. Regions that are actively involved in angiogenesis, and require the
antagonistic function of Ang-2, are, interestingly, the very same regions where Tie1
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expression is observed. Under these conditions, the majority of Tie1 and Tie2 form
signaling-incompetent heterotypic complexes on the cell surface (Figure 3.8). Their
association is dynamic and mediated via an electrostatic interaction between charged
residues within their ectodomains, as well as the presence or absence of activating ligand
(i.e. Ang-1). Cells expressing both receptors are responsive to the survival, migration,
and chemotactic cues caused by activation and inactivation of Tie2 via Ang-1 and Ang-2
and are, therefore, able to promote the required vessel branching and sprouting necessary
for angiogenesis.
Alternatively, Tie1 is absent in vascular regions that are stable and quiescent, such
as mature vessels. The absence of Tie1 negates the functional differences between Ang-1
and Ang-2 and allows endothelial cells to respond to either ligand in a similar fashion
(both as agonist), and foster the same phenotypic response-quiescence and survival
(Figure 3.8). In this regard, Tie1 serves as a selectivity factor, designating when and how
Ang-2 functions. In general, this could provide greater cellular adhesion with the
underlying vessel support cells, and provide yet another mechanism to stabilize the adult
vasculature and prevent aberrant vessel sprouting and branching that could lead to
pathogenesis.
Consistent with our proposed model, in the absence of Tie1 (Figure 3.5), Tie2
exhibits basal phosphorylation and remains partially activated despite the absence of
ligand, yet it can become further clustered and activated by both the agonist Ang-1 as
well as antagonist, Ang-2 (Davis et al., 2003; Maisonpierre et al., 1997). Alternatively, in
the presence of Tie1, the ligand-independence and basal Tie2 activity are attenuated
(Figure 3.5). In agreement, loss of Tie1 (via shRNA), eliminates the functional
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differences between Ang-1 and Ang-2 in HUVEC (Figure 3.6). Under these conditions,
endothelial cells respond to both ligands similarly. In agreement, Yuan et al. observed
that siRNA toward Tie1 significantly increased the downstream activation of Tie2
signaling components as well as its basal phosphorylation of Y992, therefore concluding
that Tie1, in it’s normal role, antagonizes Tie2 function (Yuan et al., 2007). An analogous
conclusion was drawn by Patan following histological assessment of Tie1 and Tie2
knockout mice phenotypes (Patan, 1998). In addition, Kim et al. demonstrate Ang2induced Tie2 activation following down-regulation of Tie1 via siRNA in HUVECs (Kim
et al., 2006). Similarly, Nguyen et al. observed differential responses of lymphatic versus
venous or arterial endothelial cells to Angiopoietin-1 and -2 (Nguyen et al., 2007). In line
with this observation, our model would predict that lymphatic endothelial cells, thought
to be the primary target of the Ang-2 agonist (as shown by knockout and over-expression
experiments), would display lower levels of Tie1 protein, although this has yet to be
investigated.
Some have observed Tie2 to preferentially localize at sites of cell-cell contacts
(Fukuhara et al., 2008; Saharinen et al., 2008). Indeed, our expression constructs with
and without the intracellular tyrosine kinase domain demonstrate related localization
patterns, and we, therefore, conclude that clustering to cell-cell junctions is likely
mediated by ectodomain interactions and not through the Tie2 kinase domain. While Tie2
clustering to cell junctions presents an appealing means to localize specific signaling
events, the exact mechanism by which this occurs remains unclear.
Finally, it should be noted that our studies also contrast with those by Saharinen et
al. in which Tie1 and Tie2 association is proposed to occur in the presence of Ang1 as
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Figure 3.8: Model for Angiopoietin-mediated Tie2 signaling. Expression of Tie2 in
the absence of Tie1 at sites of vessel quiescence and maturity. In the absence of Tie1,
Tie2 can be activated with either Ang-1 or Ang-2. Both ligands stimulate receptor
clustering, tyrosine kinase activity, and down-stream signaling events, effectively become
unresponsive to vessel sprouting and branching cues. Within sites of active angiogenesis,
Tie1 and Tie2 associate to form a complex prior to ligand stimulation. Upon addition of
Ang-2, Tie1 and Tie2 association and localization remains unchanged. Under these
conditions, Ang-2 fails to activate the Tie2 receptor and opposes the activation of downstream signaling generated by Ang-1. However, upon addition of Ang-1, the opposite is
observed. Ang-1 stimulates Tie2 clustering, tyrosine kinase activity, and down-stream
signaling events similar to that observed in the absence of Tie1. *Angiopoietins are
depicted as dimers for illustration purposes although they are known to exist as higherorder clusters.
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suggested by co-localization experiments (Saharinen et al., 2008). Previous reports by the
same group indicate stimulation of Tie1-Tie2 co-immunoprecipitation following Ang-1
exposure (Saharinen et al., 2005). Although we observe dramatic changes in Tie2
localization, clustering, and association with Tie1 upon binding of Ang-1, we do not see a
concomitant change in Tie1 localization. Furthermore, the extent of Tie2 clustering we
observe, is significantly greater, and FRET analysis reveals nearly immediate dissociation
of the Tie1-Tie2 complexes upon receptor stimulation. Since our analysis of receptor
complex formation is at a significantly higher resolution (<10nm versus >1µm) and more
direct, we feel the lack of change in Tie1 localization and loss of FRET documents Ang-1
induced Tie2-Tie1 complex dissociation rather than association. Furthermore, our data
and proposed function of Tie1 correlate with the observed phenotypes of Tie and Ang
knock-out mice, Tie receptor expression patterns; confirming the inhibitory effects of
Tie1 on Tie2 activation (Kim et al., 2006; Patan, 1998; Yuan et al., 2007). Collectively,
our results indicate that the balance of expression and dynamic interaction between Tie1
and Tie2 provides an effective means of controlling receptor activation, and by analogy
vascular homeostasis, using a single set of structurally similar ligands. The exquisite level
of molecular control clearly highlights the importance of restricting Tie2 activation in
order to maintain vascular homeostasis and to prevent pathogenesis; therefore, the Tie1Tie2 interface may serve as an attractive therapeutic target and may be more relevant than
the currently scrutinized Ang2-Tie2 interaction.

3.5 Materials and Methods
3.5.1 Cloning and Gene Expression
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Full-length Tie2-mCherry was constructed by fusing the fluorophore to the
carboxy terminus of Tie2 via PCR stitching using the partially complementary
oligonucleotides mCherry/TKD; gttctgctgaagaagcggccggtgcatctggttctatggccatcatcaaggag,
TKD/mCherry; ctccttgatgatggccatagaaccagatgcaccggccgcttcttcagcagaac, and mCherry
Xho; gctcactcgagctacttgtacagctcgtcc. The final construct was cloned as an NheI-XhoI
fragment into pcDNA3.1(+) hygromycin.

3.5.2 Cell Manipulations and Transfections
Human umbilical vein endothelial cells (HUVEC) were grown in EBM II media
according to recommendations (Clonetics). Cells were consistently transfected at 80-90%
confluence in 35mm glass bottom culture dishes (MatTek) using Lipofectamine 2000
(HEK293) or FuGENE HD (U2OS) or FuGENE 6 (EA.hy 926) according to
manufacturer’s

recommendations

(Invitrogen

and

Roche).

For

co-expression

experiments, equimolar concentrations of Tie1 and Tie2 vector DNA were used.

3.5.3 shRNA Knockdown of Tie1
Recombinant lentivirus encoding a Tie1 or control shRNA were constructed
according to manufacturers recommendations (Open Biosystems). Stable EA.hy 926 or
early passage HUVEC’s were selected in the presence of 0.8 ug/ml puromycin 48 hours
post viral infection. After seven days, stable cells were monitored for Tie1 and Tie2
expression via western blot analysis.

3.5.4 Tie2 Activation Assays
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For analysis of Tie2 activation in HEK293, cells were transfected with
combinations of full-length Tie1-HA, and/or Tie2-myc tagged vectors. Forty-eight hours
post-transfection, cells were lysed in HBST (20mM Hepes pH 7.4, 150mM NaCl, 0.1%
Triton X-100) in the presence of 0.5mM sodium orthovanadate and subjected to western
blotting. For Tie2 activation in HUVEC and EA.hy 926, post-confluent cells were serum
starved for 2-4 hours prior to the addition of 500ng/ml Angiopoietin-1, -2, or vehicle
(PBS). Fifteen minutes prior to ligand addition, sodium orthovanadate (Sigma) was added
to 1mM in the culture medium (Teichert-Kuliszewska et al., 2001). Fifteen minutes
following ligand addition, cells were harvested. Endogenous Tie1 and -2 were analyzed
with anti-Tie2 (Santa Cruz Biotechnology), anti-phosphotyrosine-specific 992 Tie2
(R&D Systems), or anti-Tie1 (R&D Systems and Santa Cruz Biotechnology).
Quantitative values for band intensities were obtained from western blots using the
program ImageJ. Briefly, the integrated pixel intensity was determined for each band of
interest using an identically sized rectangular masking box. The background was
similarly determined from an identical region of the blot from lanes lacking the protein of
interest - except in cases where no such lane control could be used. Under these
conditions, background was calculated from a blank region above each band of interest.
Finally, the background was subtracted uniformly from the experimental values to obtain
the final raw values. All statistical calculations were determined using JMP software
version 7.0 (SAS).

3.5.5 Cellular Imaging
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Live cell imaging was performed 24-48 hour post-transfection on a Leica TCSSP2 AOBS confocal laser scanning microscope equipped with blue diode (405nm),
Argon (458, 476, 488, 514nm). green HeNe (543nm), orange HeNe (594nm), and red
HeNe (633nm) lasers, an HCX PI Apo 63x/1.3 n.a. glycerin-immersion objective lens, a
motorized XY stage (Märzhäuser), and an environmentally controlled (temperature,
humidity, and CO2) stage incubator (PeCon). mCherry-receptor fusions and GFP were
imaged with the following excitation wavelengths; 594nm and 488nm, respectively, and
fluorescence emissions were detected with SP window settings of 605-700nm and 500560nm (for mCherry and GFP, respectively).
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Chapter 4
Function difference between Angiopoetin-1 and -2

4.1 Structural comparison of Tie2 bound to Ang-1 or Ang-2
We have previously identified the differential ability of the angiopoietins to
effectively exclude Tie1 from Tie2, affecting the phosphorylation state of Tie2.
Specifically, Ang1 is capable of excluding Tie1 from Tie2, causing Tie2 clustering on the
cell surface. Alternatively, Ang2 was incapable of excluding Tie1, causing no observed
change in Tie2 phosphorylation and localization. This led to the hypothesis that Ang-1
and Ang-2 differentially bound to Tie2, affecting the inclusion of Tie1. This however
seems unlikely with the observation that the binding of Ang1 to Tie2 does not induce
conformational changes within the extra-cellular domain (personal correspondence Dr
Dimitar Nikolov). As expected, Ang-1 bound to the same region of Tie2 with the same
affinity as observed with the Ang2-Tie2 structure (Barton et al., 2006; Davis et al, 2005).
The specificity of Ang2 for Tie2 involves 13 residues (S417, K432, I434l, D448, A449,
P452, N467, K468, F469, K473, Y475, Y476, S480) in the P-domain close to the
calcium-binding site (Barton et al., 2006). Mutagenesis studies revealed K468, F469,
K473, Y475, and Y476 attenuated the binding of Ang-2 to Tie2 (Barton et al., 2005). Of
these residues, 3 are conserved (Ang2 K468-Ang1 K468, Ang2 K473-Ang1 K475, Ang2
Y476-Ang1 Y478) with an additional 1 being homologous (Ang2 F469-Ang1 Leu471).
Tyr475 in Ang-2 makes van der Waals contact with P166 in Tie2. The corresponding
position in Ang1, H477 could make similar contacts. As such, this minor change is not
likely the differential function between the angiopoietins with Tie2 mutant F161A/S164E
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unable to bind to either Ang-1 or Ang-2 (Barton et al., 2006). These observations lead us
to hypothesis the ligands differential functions involved their ability to exclude Tie1 from
Tie2 and not their ability to structurally modify the Tie2 receptor.

4.2 Identification of Angiopoietin residues involved in altering Tie1-Tie2 formation
Analysis of the crystal structures of Ang1 or -2 bound to the same region of Tie2,
utilizing similar contact points lead us to examine amino acids outside of those used to
recognize Tie2. The angiopoietin family members, 1-4, share high sequence homology
within the receptor-binding domain allowing for identification of amino acids that can
alter the Tie1-Tie2 interaction to be identified.

Figure 4.1 is a surface rendering

homology map of the receptor-binding domain of Ang-2 (Barton et al., 2005). Regions
colored in red are considered to be 100% conserved across all four angiopoietins where
as regions colored in blue, green, and grey share 75%, 50%, 0% conservation,
respectably.

The yellow circle represents the surface area buried by the Ang-Tie2

interaction. As indicated by the structural analysis of Ang-1 or -2 bound to Tie2, there is
a great deal of sequence conservation among these residues involved in mediating this
interaction. By observing Ang-1 or -2 bound to Tie2 with similar folds, we only took
surface residues into consideration and hypothesized these residues will not cause large
conformational changes but support the inclusion of Tie1 by either ionic or van der Waals
interactions. Interestingly, a region of low conservation and a change in ionic residues
was identified in the P-domain outside of the receptor ligand interface, as highlighted in
Figure 4.1 by the arrow. Furthermore, this region appears cis to the co-receptor interface
identified in our earlier studies, Chapter 2 Figure 2.5B. Sequence alignment of the
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Figure 4.1: Homology model of Angiopoietin Receptor Binding Domain. Surface
residues on the angiopoietin receptor-binding domain were color-coded based upon their
sequence conservation across Ang1-4, with 100%, 75%, 50%, 0% depicted as red, blue,
green, and grey, respectably. The yellow ring indicates the amino acids responsible for
Tie2 receptor binding. The arrow indicates the none conserved PQR ionic loop.
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angiopoietins identified the residues as P460/Q461/R462 in Ang-2 and T462/A463/G464
in Ang-1. The presence of basic residues in Ang-2 would suggest, binding of Ang-2 to
Tie2 would allow these residues to interact with Tie1, stabilizing the hetero-Tie receptor
complex.

4.3 Phenotypic swapping of Ang2
To test the plausibility of Ang-2 in stabilizing the Tie1-Tie2 complex, we utilized
site-directed mutagenesis in combination with the proximity assay utilized in Chapter 2
(Figure 2.1). It has been our experience in modulating protein-protein interactions;
multiple simultaneous mutations should be utilized (Barton et al., 2003).

As such,

multiple mutations were made in an Ang2-Fc fusion tagged protein to resemble Ang-1 in
its corresponding positions, swapping the P460/Q461/R462 to T460/A461/G462. The
angiopoietin ligand requires clustering for its utility in endothelium cell based assays to
elicit Tie2 phosphorylation (Davis et al., 2005; Kim et al., 2005).

Although many

attempts have been made in the past, we are unable to produce full-length angiopoietin
using standard protein production methods. To avert this issue we adopted methodology
from the Yancopoulos group, by producing the angiopoietin receptor-binding domain as
an Fc fusion protein, capable of clustering by means of exogenously added anti-Fc
antibody (Davis et al., 2005). As measured by the phosphorylation of tyrosine 992 in the
activation loop in Tie2, our Ang1-Fc fusion protein was capable of activating Tie2 when
clustered by the addition of an anti-Fc antibody whereas the clustered Ang2-Fc acted as
an antagonist (Figure 4.2, lanes 7-10). The phosphorylation levels were in agreement
when HUVECs were challenged with native Ang1 ligand (Compare lanes 3 and 8). In
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Figure 4.2: Phosphorylation of Tie2 by the Fc angiopoietin ligands. Asynchronous
HUVECs were subjected to four hours of serum withdrawal, followed by the listed
ligand. After 30 minutes, cells were harvested and subjected to western blotting with
anti-Tie2 (middle panel) and the phosphotyrosine specific anti-Tie2 (992) (top panel), as
indicated. The relative ratio of phosphorylated Tie2 (top panel) over total Tie2 (middle
panel) was determined and the calculated value was arbitrarily set equal to 1.0 for
unstimulated Tie2. Values are graphically displayed below each respective lane.
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agreement with other reports on the ligand-clustering requirement for angiopoietin
induced Tie2 signaling, in the absences of the clustering antibody, neither Ang1-Fc nor
Ang2-Fc was capable of activating Tie2 (Compare lanes 5-6 and 7-10) (Davis et al.,
2005; Kim et al., 2005).

As such, these observations validate the usage of the

angiopoietin Fc fusion proteins in monitoring their effect on Tie2 and Tie1. Furthermore,
we now have a platform in which mutant angiopoietins can be created allowing us to test
these mutant variants on their effects on Tie2.

4.4 Angiopoietin modulation of Tie1-Tie2 measured by FRET
To further evaluate the angiopoietin-Fc fusion proteins ability to modulate the
Tie1-Tie2 complex, we utilized our FRET based proximity assay from Chapter 2. In
brief, transient transfections of epithelial cells were performed using our chimeric Tie1CFP and Tie2-YFP receptors. Epithelial cells were utilized for their ease in transfection
and the lack of endogenous Tie receptors. We have previously shown the Tie1-Tie2
interaction is not differentially modified in response to cell type (Figure 2.2).

As

expected, proper membrane localization of these receptors was observed (Figures 4.3 and
4.4). As previously observed, in the absence of ligand Tie1 readily interacts with Tie2
and the average initial FRET efficiency was determined by the acceptor photo bleaching
method to be 24.8% (Figure 4.5). Observing the antibody clustered Ang1-Fc and not the
clustered Ang2-Fc was capable of inducing Tie2 phosphorylation, we hypothesized only
the clustered Ang1-Fc was capable of causing a loss in FRET efficiency between Tie1
and Tie2. As such, no statistical change in FRET was observed after 30 minutes when
cells expressing both Tie1 and Tie2 were challenged with either the clustering antibodies
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Figure 4.3: The clustering antibodies and clustered Ang2-Fc do not affect the Tie1Tie2 receptor complex. U2OS cells were transiently transfected with the chimeric Tie1CFP and Tie2-YFP receptors. At (A) time=0 either (B) clustering antibodies or (C)
clustered Ang2-Fc was added to the growth media and imaged after 30 minutes. FRET
was determined by acceptor photobleaching by bleaching YFP within a region of interest,
green box, localized to the cellular membrane.
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or the clustered Ang2-Fc. Average FRET efficiencies were determined for the antibody
control and clustered Ang2-Fc to be 24.2% and 15.2%, respectably (Figure 4.5).
Furthermore, Tie2 localization remains unchanged under these conditions; representative
images can be seen in Figure 4.3B-C. The inability to induce Tie2 phosphorylation and
stabilize the Tie1-Tie2 co-receptor complex allows us to conclude the clustered Ang2-Fc
fusion protein behaves similar to the native Ang2 ligand.
In contrast to the sustained FRET efficiency measured between Tie1 and Tie2
with the clustered Ang2-Fc, a dramatic loss in FRET between Tie1 and Tie2 is observed
when treating cells with the clustered Ang1-Fc. After 30minutes of treatment with the
clustered Ang1-Fc fusion protein, a dramatic change in Tie2 localization was observed,
changing from confluent membrane localization to more punctate, as indicated by the
arrows in Figure 4.4A. The change in Tie2 localization was similar to that observed
localization of Tie2 in epithelial and endothelial cells challenged with native Ang-1
(Figure 3.1 and 3.2, respectably). Similar to our prior studies, Tie1 localization remained
unchanged

with

continued

confluent

localization

to

the cellular

membrane.

Consequentially, with the change in Tie2 localization a loss in FRET efficiency between
Tie1 and Tie2 was observed after 30minutes. The average FRET efficiency measured
after 30 minutes was equal to 0.49%. These observations led us to conclude the Ang1-Fc
fusion protein was capable of inducing Tie2 phosphorylation in a similar manner as the
native Ang-1 ligand. Both ligands appear to induce Tie2 activation by clustering the Tie2
receptor and further excluding Tie1.
We next sought to test the effect our clustered mutant Ang2-TAG-Fc protein
would have on modulating the Tie1-Tie2 co-receptor complex. Treatment of epithelial
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Figure 4.4: The clustered Ang1-Fc and clustered mutant TAG Ang2-Fc affect the
Tie1-Tie2 receptor complex. U2OS cells were transiently transfected with the chimeric
Tie1-CFP and Tie2-YFP receptors. At time=0 either (A) clustered Ang1-Fc or (B)
clustered mutant TAG Ang2-Fc was added to the growth media and imaged after 30
minutes. FRET was determined by acceptor photobleaching by bleaching YFP within a
region of interest, green box, localized to the cellular membrane.

92
A.

B.

93

Figure 4.5: Graphical representation of average FRET efficiencies after 30minutes
of stimulation with AngFc varients. The date is represented as mean +/- SEM with an
n=3.
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cells expressing Tie1 and Tie2 with the clustered mutant Ang2-TAG-Fc fusion protein
resulted in a similar Tie receptor localization when treated with the clustered Ang1-Fc
fusion protein. As seen in Figure 4.4B, Tie2 localization is altered on the cell surface and
results in a corresponding loss in FRET efficiency between Tie1 and Tie2. It should be
noted the extent of Tie2 localization was not as dramatic as compared to cells treated
with Ang-1.

More importantly, the average FRET efficiency after 30 minutes was

observed to equal 3.6% (Figure 4.5). This loss in FRET upon treatment is statistically
different from the Ang2-Fc and antibody control values and similar to values obtained
upon Ang1 treatment. These observations led us to conclude the mutant Ang-TAG-2 had
switched its phenotype, causing it to act as an agonist to Tie2.

4.5 Structural Determination of the mutant Ang-TAG-2
The observed phenotypic change in the mutant Ang-TAG-2 led us to evaluate the
effect TAG point mutations had on the globular strucuture. The mutant Ang-TAG-2
structure solved at 1.9Å by molecular replacement and refined with an R factor 20.0%
(RFree=22.5%). The structure folds into the expected fibrinogen domain observed for
Ang-1 and -2 (Figure 4.6A). Superimposition of the mutant Ang-TAG-2 structure onto
the wild type Ang-2 reveals two almost identical structures with an r.m.s. deviation of
0.58 Å of equivalent Cα positions, well into the range of experimental error (Figure
4.6B). The most prominent difference between corresponding Cα positions was observed
for the arginine (R462) to glycine (G462) mutation. The r.m.s. deviation of this position
was 1.76 Å moving the loop outward from the Tie2 receptor binding interface (Figure
4.6C). The similarity between these two structures reveals, the PQR/TAG mutants does
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Figure 4.6: Structural determination of the mutant TAG Ang2. (A) Ribbon diagram
of the mutant TAG Ang2 fibrinogen domain. The TAG loop is highlighted in green with
the Ca2+ in the P-domain depicted as a black sphere. (B) Cα traces of mutant TAG Ang2
(Blue) overlaid the wild type Ang2 (orange) fibrinogen domain. (C) A magnified view of
the TAG loop.
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not induce any large conformation changes to account for the difference in Tie2
activation. This was also expected as we have previously observed the Ang-1 and Ang-2
structures to adopt similar folds. The high similarity between the mutant Ang-2 structure
with the wild type Ang-2 structure depicts the importance of the ionic interaction of the
QR in Ang-2 with keeping Tie1 bound to Tie2.

4.6 Conclusions
We have previously demonstrated that the functional differences among the
angiopoietin ligands are attributed to their ability to modulate the Tie1-Tie2 receptor
complex. However, our previous research failed to highlight the molecular mechanisms
within Ang-1 and -2 that could manipulate the Tie1-Tie2 interaction. The Angiopoietins
share significant sequence homology, and we have previously demonstrated with
structural and mutagenesis data that differential binding to Tie2 appeared unlikely to
mediate this mechanism (Barton et al, 2005; Barton et al., 2006). Therefore, in an attempt
to further understand Angiopoietin differences at the atomic level, we structurally
characterized Ang-1 and the Ang-1/Tie2 complex in addition to our previously
determined Ang-2 and Ang-2/Tie2 complex structures. As expected, the ligands share
significant structural similarity within the fibrinogen subdomains; A, B, and P.
Furthermore, Ang-1 and Ang-2 form similar complexes with Tie2 despite their functional
differences (Davis et al., 2003). Residues involved in receptor-ligand interactions are
fairly conserved; as such, ligand binding to Tie2 is not substantially different between
Ang-1 or Ang-2. Therefore, it appears more likely that residues outside of the receptorbinding site must influence Tie1-Tie2 interactions and mediate their functional
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differences. Indeed, analysis of ligand conservation and molecular modeling suggested
only a few possibilities that could be utilized to determine the functional difference
between Ang-1 and -2. Analysis of the Ang-2 fibrinogen domain cis to the Tie1-Tie2
binding interface revealed an ionic loop of low sequence conservation we hypothesized
was capable of interacting with Tie1. The corresponding loop in Ang-1 was considerably
less ionic. Cellular studies using our FRET based proximity assay successfully identified
this ionic loop of Ang-2 as the major contributing force in stabilizing the Tie1-Tie2 coreceptor complex on the cell surface.

Based on our knowledge of the Tie1-Tie2

interaction, which is dominated by electrostatic contacts, it was not unexpected that a
charged surface residue is among those involved in ligand differentiation. Indeed, the
TAG mutant replaces an arginine with the unbranched glycine residue, suggesting Ang-2
further stabilizes the Tie1-Tie2 complex via electrostatic interactions. Unfortunately,
without further structural characterization of the Tie1-Tie2 receptor complex,
identification of surfaces residues in Tie1 that mediate this interaction are not apparent.
Another explanation could be the involvement of yet another unidentified co-receptor to
Tie2 when bound by Ang-1. Tie2 has been shown to interact with the integrins α5β1
(personal communication with Dr Dimitar Nikolov).

Therefore, it is possible these

mutations in Ang-2 could perturb further binding to these co-receptors, affecting the
inclusion of Tie1 to Tie2. Experiments are currently being conducted to addresses these
possible interactions.
In conclusion, we demonstrate that only three critical residues within the
Angiopoietin fibrinogen domain are necessary to differentiate a receptor agonist from
antagonist, thus highlighting the significance of subtle interactions in nature. In light of

100
these findings, we would predict that therapeutics targeting this region within Ang-2
would be both highly specific and beneficial in blocking Tie2 induced angiogenesis.

4.7 Materials and Methods
4.7.1 Cloning and Mutagenesis
The human Ang-1 and Ang-2 receptor-binding domains (RBD) (residues Ang-1:
278-498, and Ang-2: 276-496) were cloned as an IgG fusion protein into a modified
pcDNA3.1 vector (Invitrogen) for constitutive over-expression in a human embryonic
kidney 293 (HEK293) cell line as previously described (Barton et al., 2005). Human
recombinant Ang-1 and Ang-2 were purchased from R&D Systems. The TAG mutations
within Ang-2 coding regions were introduced by site directed mutagenesis (Quikchange
Multi, Stratagene) following manufacturers recommendations. The primer sequence:
GGAATGTACTATACTGCAGGCCAGAACACAAATAAG. To confirm the presence
of the desired mutations, both DNA strands were sequenced using standard di-deoxy
sequencing chemistry (Cornell University Bioresource Center).

4.7.2 Protein Expression and Crystallization
Large-scale protein expression was performed with stable HEK293 cells
expressing the angiopoietin receptor binding domain Fc-fusion proteins in a BioFlo310
bioreactor (New Brunswick Scientific) or roller-bottle culture with typical yields
averaging 10 mg/L. Protein was purified from conditioned media by affinity
chromatography on Protein-A sepharose, cleaved off the Fc-fusion tag via thrombin
proteolysis, and further purified by gel-filtration chromatography. The following nine
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vector-derived residues remain at the C- terminus following thrombin cleavage:
GSASGLVPR. All of the human angiopoietin receptor-binding regions were expressed
and purified as described (Baton et al., 2005). In brief, angiopoietin receptor binding
domains were purified from conditioned media by affinity chromatography on Protein-A
sepharose. Following elution and buffer exchange from the Protein-A column, Fc-fusion
tag was cleaved off via thrombin proteolysis, and the angiopoietin receptor-binding
domain was further purified by a sepharose SD200 gel-filtration column. The following
nine vector-derived residues remain at the C- terminus following thrombin cleavage:
GSASGLVPR. For angiopoietin receptor binding domains not requiring cleavage of the
Fc-fusion tag, further purification required only the utility of the sepharose SD200 gelfiltration column to yield pure material for cell based assays.
For the mutant Ang2 structural determination, purified protein was concentrated
to 15mg/mL in buffer containing 20 mM HEPES pH 7.4 and 150 mM NaCl and
crystallized by hanging drop vapor diffusion at room temperature (20˚C). Crystals were
initially observed grown out of 1.0 M K/Na Tartate, 0.1M Tris pH 7.0, and 0.2 M
Li2SO4. This condition was optimized to yield larger crystals by growing in 0.9 M K/Na
Tartate, 0.1M Tris pH 7.0, and 0.2 M Li2SO4. Crystals were harvested by quickly
transferred to a cryo-buffer consisting of mother liquor supplemented with 20% ethylene
glycol as a cryoprotectant and flash frozen in liquid nitrogen.

4.7.3 Structural determination
The structural data for Ang-2 TAG was collected on the X-ray Operations and
Research beamline 23-ID-B at Advanced Photon Source, Argonne National Laboratory.
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Initially, the program AMORE was used to identify the location of the fibrinogen domain
using the Ang-2 RBD (PDB Id 1Z3S) as a search model. Subsequent refinement
proceeded with iterative rounds of model adjustments (using the molecular graphics
program O), molecular dynamics, and energy minimization in CNS (Brunger et al., 1998;
Jones et al., 1991). In an attempt to keep the model unbiased within the loop containing
the TAG mutations, residues 467 - 476 were omitted in the initial search model. The
model was subsequently subjected to additional rounds of refinement within the CNS
suite prior to manually building the missing region using the graphical program O.
Stereochemical analysis of the refined models using PROCHECK (CCP4 Suite) revealed
main chain and side chain parameters better than or within the typical range of values for
protein structures.

4.7.4 Cell Imaging
For FRET cell stimulations with the angiopoietin Fc-fusion proteins, 2ug/mL of
the angiopoietin Fc-fusion protein were allowed to incubate for 30 minutes at room
temperature (20˚C) in 1mL of DMEM supplemented with a 2-fold molar excess of rabbit
anti-human Fc-fragment specific (Jackson Immuno-Research) and goat anti-rabbit IgG
(Jackson Immuno-Research) antibodies. The condition media was then placed over the
cells and FRET images were obtained after 20 minutes of stimulation.

FRET was

determined between the Tie2-YFP and Tie1-CFP chimeric receptors as described in
Chapter 2. All statistical calculations were determined using JMP software version 7.0
(SAS).
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4.7.5 Tie2 activation Assays
For Tie2 phosphorylation analysis, post-confluent HUVECs were serum starved
for 2-4 hours prior to the addition of 500ng/ml Angiopoietin-1, -2, or vehicle (PBS).
Fifteen minutes prior to ligand addition, sodium orthovanadate (Sigma) was added to
1mM in the culture medium (Teichert-Kuliszewska et al., 2001). Fifteen minutes
following ligand addition, cells were harvested.

For HUVECs stimulated with the

angiopoietin Fc-fusion proteins, 2ug/mL were added to the cells and allowed to
equilibrate for 5 minutes. The clustering antibodies, rabbit anti-human Fc fragment
specific and goat anti- rabbit IgG, were sub sequentially added to the media in a 2-fold
molar excess of the angiopoietin Fc-fusion proteins. The cells were allowed to incubate
at 37˚C for an additional 15 minutes then harvested by in-dish lyses with 10% NP-40,
HBS, 1mM sodium orthovanadate, and Completen (Fisher Scientific) protease cocktail
inhibitor. Phosphorylation of Tie2 was performed as described in Chapter 3.
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Chapter 5
Conclusions

Prior to this study, understanding the molecular role Tie1 had in angiopoietinTie2 signaling remained at the forefront of vasculature research. As such, the aim of this
research was to identify a molecular role for Tie1 in angiopoietin signaling of Tie2. The
Tie receptors share high sequence homology and have both been shown through genetic
mouse studies to be essential for developmental angiogenesis. Both receptors appear to
have conflicting roles in angiogenesis with the activation of Tie2 leading to vessel
quiecesencs and the up regulation of Tie1 observed at sites of angiogenesis. Initial
structural analysis of Tie1 based on Tie2 revealed the presence of basicly charged surface
area capable of mediating an interaction to an acidicly charged region of Tie2. To
evaluate this hypothesis, we utilized a powerful biophysical proximity FRET assay to
evaluate the potential interaction between the extracellular portions of Tie1 and Tie2. We
found in the absence of ligand, these two receptors readily localized and formed a heterocomplex on the cells surface. Mutation analysis within the binding interface revealed the
importance of this interface in mediating a direct interaction between the Tie1 and Tie2
receptors. We further evaluated the ability of the hetero-receptor complex to persist upon
stimulating cells with the angiopoietin ligands, Ang-1 and Ang-2. Angiopoietin-1 acted
as a constitutive agonist to Tie2, eliciting receptor clustering and phosphorylation
independent of Tie1 expression. Conversely, angiopoitin-2 only acted as an agonist to
Tie2 in the absence of Tie1. Structural analysis of either Ang-1 or -2 bound to Tie2
revealed similar binding mechanisms. As such we identified a loop in the P-domain of
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the angiopoietins’ receptor recognition domain that could account for the inclusion or
exclusion on Tie1 from Tie2. From this research we were able to develop a unified
model in which Tie1 attenuates Tie2 activation. In the absence of Tie1 the angiopoietin
ligands are indistinguishable to the endothelium acting as an agonist to Tie2, leading to
vessel stability. Although, in the presence of Tie1, Ang-1 continues to act as an agonist
to Tie2 but Ang-2 now acts as an antagonist causing the vessel to increase its
permeability. The attenuation of Tie2 signaling causes the vessel to become preamble to
chemotatic signaling leading to either vessel regression or sprouting. Through this study
we have identified a molecular mechanism for Tie1 in angiopoietin Tie2 signaling and
identified novel targets for drug design to combat tumor growth.
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